This fixed combination drug is not indicated for initial therapy of hypertension. Hypertension requires therapy titrated to the individual patient. If the fixed combination represents the dose so determined, its use may be more convenient in patient management. The treatment of hypertension is not static, but must be re-evaluated as conditions in each patient warrant.
MINIZIDE® is a combination of MINIPRESS® (prazosin hydrochloride) plus RENESE® (polythiazide). MINIPRESS (prazosin hydrochloride), a quinazoline derivative, is the first of that chemical class of antihypertensives.
MINIZIDE is indicated in the treatment of hypertension. (See box warning.)
Media Articles Related to Minizide (Prazosin / Polythiazide)
New AHA Statement on Hypertension and Cognitive Function
Source: Medscape NeurologyHeadlines [2016.10.13]
A new statement from the American Heart Association recommends 'judicious' treatment of high blood pressure to protect against subsequent cognitive decline.
Medscape Medical News
AHA Statement: Hypertension, Dementia Linked (CME/CE)
Source: MedPage Today Nephrology [2016.10.12]
(MedPage Today) -- "Judicious" antihypertensive tx suggested despite limited evidence
Hypertension in children, teens linked to poorer cognitive skills
Source: Hypertension News From Medical News Today [2016.09.30]
Researchers found that children and adolescents with high blood pressure performed worse on cognitive tests than those with normal blood pressure.
Innovative sound therapy treats hypertension and migraine
Source: Headache / Migraine News From Medical News Today [2016.09.17]
A groundbreaking device that aligns the left and right brain using sound alone may reduce the symptoms of migraine, hypertension, and insomnia.
Hypertension: Releasing the pressure at its source
Source: Hypertension News From Medical News Today [2016.09.07]
Researchers eyeing first new anti-hypertensive drug treatment strategy in more than 15 years.
Page last updated: 2016-10-13